Press "Enter" to skip to content

USFDA issues 5 observations to Dr Reddy’s plant in Hyderabad

"The audit of our active pharmaceutical ingredient (API) manufacturing plant 2 at Bollaram, Hyderabad by the United States Food and Drug Administration (USFDA), has been completed today," Dr Reddy’s said in a filing to BSE.

Original source:

Also Read:   Clinic waiting room in Harlem becomes experiment in humanizing medicine